Nature17d
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
T ratios (Figures 3a and b). To further investigate the specificity of CD5CAR NK-92 cells in targeting CD5 + populations and potential off-target effects, we analyzed co-culture assays with T-ALL ...
Morningstar24d
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
MB-105 is a first-in-class autologous CD5-targeted CAR-T cell therapy in development for CD5-positive hematologic malignancies, including T-cell lymphoma (TCL), T-cell acute lymphoblastic leukemia ...
Pharmabiz22d
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Beyond MB-105, March Bio is advancing a robust pipeline of cell therapies to further expand its potential to improve treatment options for difficult diseases and malignancies. MB-105 is a ...